All In MedTech

FDA Clearance Tracker · P150040-S003

VisuMax Femtosecond Laser

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 4, 2018 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 4, 2018

Approved

Time to decision

195 days

Received Mar 23, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P150040-S003
Device name
VisuMax Femtosecond Laser
Applicant location
Dublin, CA
Received
Mar 23, 2018
Decided
Oct 4, 2018
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P150040

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code OTL

FDA's approval statement

As written in FDA's record.

Approval for the VisuMax Femtosecond Laser. This device is indicated for use in small incision lenticule extraction (SMILE) for the reduction or elimination of myopia with or without astigmatism:1) For spherical refractive error (in minus cylinder format) from -1.00 diopters through -10.00 diopters;2) For cylinder from -0.75 diopters through -3.00 diopters; and3) When refraction spherical equivalent is no greater in magnitude than 10.00 diopters, in patients 22 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of less than or equal to 0.50 D in magnitude.

Source documents

Other decisions for Carl Zeiss Meditec, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.